Lantern Pharma Inc.
General ticker "LTRN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $37.0M (TTM average)
Lantern Pharma Inc. follows the US Stock Market performance with the rate: 8.6%.
Estimated limits based on current volatility of 5.3%: low 2.34$, high 2.60$
Factors to consider:
- Total employees count: 60 (+160.9%) as of 2023
- Top business risk factors: Need substantial additional funding, Economic downturns and volatility, Product development failure, Regulatory and compliance, Limited market acceptance
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.29$, 5.82$]
- 2026-12-31 to 2027-12-31 estimated range: [2.17$, 5.54$]
Financial Metrics affecting the LTRN estimates:
- Positive: with PPE of -2.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -43.00 <= 0.30
- Positive: Investing cash flow per share per price, % of 30.33 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: 42.34 < Shareholder equity ratio, % of 59.21 <= 63.79
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
Short-term LTRN quotes
Long-term LTRN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $17.88MM | $22.22MM | $17.98MM |
| Operating Income | $-17.88MM | $-22.22MM | $-17.98MM |
| Non-Operating Income | $1.92MM | $1.44MM | $0.86MM |
| R&D Expense | $11.89MM | $16.13MM | $11.51MM |
| Income(Loss) | $-15.96MM | $-20.78MM | $-17.12MM |
| Net Income(Loss)* | $-15.96MM | $-20.78MM | $-17.12MM |
| Stockholders Equity | $40.91MM | $21.19MM | $6.53MM |
| Assets | $43.65MM | $25.57MM | $11.04MM |
| Operating Cash Flow | $-14.35MM | $-17.81MM | $-15.68MM |
| Capital expenditure | $0.02MM | $0.01MM | $0.00MM |
| Investing Cash Flow | $-0.93MM | $3.37MM | $11.06MM |
| Financing Cash Flow | $-0.50MM | $0.07MM | $1.50MM |
| Earnings Per Share** | $-1.47 | $-1.93 | $-1.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.